WIN 552122

Drug Profile

WIN 552122

Alternative Names: WIN 55212; WIN 55212-2

Latest Information Update: 20 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi Winthrop
  • Developer Sanofi Winthrop; University of Minnesota
  • Class Antiparkinsonians; Cannabinoids; Neuroprotectants
  • Mechanism of Action Cannabinoid receptor agonists; Cannabinoid receptor CB1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Glaucoma; Movement disorders; Neurological disorders; Pain

Most Recent Events

  • 20 Feb 2006 Discontinued - Preclinical for Glaucoma in USA (Ophthalmic)
  • 20 Feb 2006 Discontinued - Preclinical for Movement disorders in USA (unspecified route)
  • 20 Feb 2006 Discontinued - Preclinical for Neurological disorders in Spain (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top